Brenda Hug
Papers
1
Total Citations
2
H-Index
1
About
Dr. Brenda Hug is a leading urologic oncologist whose research focuses on bladder cancer surveillance, liquid biopsy technologies, and precision oncology. Her most impactful work investigates the clinical utility of circulating tumor DNA (ctDNA) as a biomarker for guiding post-surgical monitoring. In her landmark 2025 study, she demonstrated that bladder cancer patients with undetectable ctDNA after radical cystectomy may safely undergo less intense imaging surveillance—a finding that could reduce unnecessary radiation exposure and healthcare costs while maintaining diagnostic accuracy. This work has already garnered attention for its potential to shift standard-of-care protocols. Dr. Hug’s contributions are particularly notable for bridging molecular diagnostics with practical clinical decision-making, offering a personalized approach to cancer follow-up. Her research, cited in emerging guidelines, underscores the promise of ctDNA in minimizing overtreatment and improving quality of life for survivors. By integrating cutting-edge genomics with patient-centered outcomes, Dr. Hug is shaping a future where surveillance intensity is tailored to individual molecular risk.
Research Focus
Key Achievements
Top Papers
- 1